Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Increased by Institute for Wealth Management LLC.

Institute for Wealth Management LLC. lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 1.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,426 shares of the life sciences company’s stock after purchasing an additional 42 shares during the quarter. Institute for Wealth Management LLC.’s holdings in Illumina were worth $898,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of ILMN. EFG Asset Management Americas Corp. raised its position in Illumina by 5.7% during the second quarter. EFG Asset Management Americas Corp. now owns 9,851 shares of the life sciences company’s stock valued at $3,648,000 after acquiring an additional 529 shares in the last quarter. Peregrine Capital Management LLC raised its position in Illumina by 3.3% during the second quarter. Peregrine Capital Management LLC now owns 91,781 shares of the life sciences company’s stock valued at $33,991,000 after acquiring an additional 2,923 shares in the last quarter. Lyell Wealth Management LP raised its position in Illumina by 0.9% during the second quarter. Lyell Wealth Management LP now owns 16,327 shares of the life sciences company’s stock valued at $6,047,000 after acquiring an additional 150 shares in the last quarter. State of Michigan Retirement System raised its position in Illumina by 11.7% during the second quarter. State of Michigan Retirement System now owns 37,583 shares of the life sciences company’s stock valued at $13,919,000 after acquiring an additional 3,923 shares in the last quarter. Finally, Duality Advisers LP bought a new position in Illumina during the second quarter valued at approximately $2,621,000. 89.86% of the stock is owned by institutional investors and hedge funds.

In other Illumina news, SVP Aimee L. Hoyt sold 191 shares of Illumina stock in a transaction on Monday, June 8th. The shares were sold at an average price of $350.94, for a total transaction of $67,029.54. Following the sale, the senior vice president now owns 3,498 shares in the company, valued at $1,227,588.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Frances Arnold sold 1,503 shares of Illumina stock in a transaction on Monday, May 11th. The stock was sold at an average price of $309.11, for a total transaction of $464,592.33. Following the sale, the director now owns 9,954 shares in the company, valued at approximately $3,076,880.94. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,707 shares of company stock worth $10,819,532. 0.38% of the stock is currently owned by corporate insiders.

Shares of Illumina stock traded down $0.62 during midday trading on Friday, hitting $382.16. The company had a trading volume of 933,505 shares, compared to its average volume of 773,438. The business’s 50 day simple moving average is $370.94 and its two-hundred day simple moving average is $319.27. The stock has a market cap of $56.18 billion, a PE ratio of 60.18, a P/E/G ratio of 5.65 and a beta of 1.00. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.10 and a quick ratio of 3.74. Illumina, Inc. has a 1-year low of $196.78 and a 1-year high of $402.14.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.39. The business had revenue of $859.00 million for the quarter, compared to the consensus estimate of $857.92 million. Illumina had a net margin of 26.48% and a return on equity of 21.78%. Illumina’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the company posted $1.60 earnings per share. On average, sell-side analysts expect that Illumina, Inc. will post 6.15 EPS for the current fiscal year.

ILMN has been the topic of several recent research reports. Stifel Nicolaus raised their price objective on shares of Illumina from $298.00 to $325.00 and gave the company a “buy” rating in a research report on Friday, May 1st. BidaskClub raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Piper Sandler dropped their price target on shares of Illumina from $370.00 to $356.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Wells Fargo & Co lifted their price target on shares of Illumina from $245.00 to $290.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. Finally, Guggenheim lowered shares of Illumina from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 7th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $343.20.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Recommended Story: Average Daily Trade Volume – ADTV

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.